Status:

WITHDRAWN

Study of the Vascular Response to Percutaneous Coronary Intervention in Patients With Non-ST-elevation Acute Coronary Syndromes Using Intravascular Blood Sampling

Lead Sponsor:

Sheffield Teaching Hospitals NHS Foundation Trust

Conditions:

Non ST Segment Elevation Acute Coronary Syndrome

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

This interventional study is using the PlaqueTec LBS will enrol participants already undergoing coronary angiography as a component of their standard care for NSTE-ACS. The study will involve no chang...

Detailed Description

This clinical protocol will be subject to peer review according to standard local procedures, including independent scientific review by the Scientific Advisory Board of the Clinical Research Facility...

Eligibility Criteria

Inclusion

  • Aged over 18 years
  • Admitted to hospital with non-ST-elevation ACS and plan for either coronary angiography with a view to PCI if appropriate or PCI following coronary angiography at a referring hospital
  • Current treatment with aspirin and ticagrelor or, if ticagrelor is not tolerated, prasugrel (DAPT)
  • Ability to give informed consent

Exclusion

  • Treatment with antiplatelet medication apart from aspirin, ticagrelor, prasugrel or clopidogrel in the last 10 days (e.g. dipyridamole, abciximab, tirofiban).
  • Planned use of a glycoprotein IIb/IIIa antagonist for the PCI procedure.
  • Patients with haemodynamic instability, shock or angiographic evidence of intracoronary thrombus.
  • Current use of an oral anticoagulant (e.g. warfarin, dabigatran, rivaroxaban, apixaban).
  • Clinically significant liver disease.
  • Contraindication or allergy to unfractionated heparin.
  • Receiving immunosuppressant medication (eg. cyclosporin, tacrolimus, mycophenolate, azathioprine).
  • Administration of doses of low molecular weight heparin or fondaparinux in the 12 hours preceding PCI.
  • Known severe left ventricular dysfunction (ejection fraction \<30%).
  • Culprit lesion in left main coronary artery.
  • Women of childbearing potential unless pregnancy has been excluded during the index hospital admission.
  • Known serum creatinine above upper limit of local reference range.
  • Subjects with known active chronic inflammatory disease, e.g. systemic lupus erythematosus, rheumatoid arthritis, seropositive arthropathies and known seropositivity to HIV, Hepatitis B or Hepatitis C.
  • Severely diseased, excessively tortuous or calcified coronary vessels that increase the risk of snaring the LBS.
  • Culprit lesion in a coronary vessel with a reference diameter of less than 2.5 mm.
  • Need to cross a region of coronary vessel that contains a stent.
  • Evidence of ongoing sepsis.
  • Receiving a non-steroidal anti-inflammatory drug (NSAID) apart from aspirin, including selective COX2 inhibitors ('coxibs') and including regular or intermittent/as required use.
  • Receiving a strong inhibitor of CYP3A4 (eg, ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin \[but not erythromycin or azithromycin\], nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atanazavir, or over 1 litre daily of grapefruit juice).
  • Receiving simvastatin or lovastatin at doses higher than 40 mg daily.
  • Receiving a CYP3A substrate with a narrow therapeutic index (e.g. cyclosporine or quinidine).
  • Receiving a strong inducer of CYP3A (e.g. rifampin/rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital).
  • Current or recent (within 30 days) participation in a clinical trial of a drug or device or any other clinical study that might influence the results or safety of the study.
  • Any factor precluding ability to comply with follow-up.
  • Any other factor judged by the investigator or treating physician to preclude enrolment in the study.

Key Trial Info

Start Date :

November 30 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 30 2020

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT03300167

Start Date

November 30 2017

End Date

June 30 2020

Last Update

March 17 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Sheffield Teaching Hospitals NHS Foundation Trust

Sheffield, South Yorkshire, United Kingdom, S5 7AU